Daclizumab in the Induction Phase of Immunosuppression in Heart Transplant Recipients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209775%3A_____%2F05%3A%230000041" target="_blank" >RIV/00209775:_____/05:#0000041 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Daclizumab in the Induction Phase of Immunosuppression in Heart Transplant Recipients

Original language description

We assessed the incidence and severity of acute rejection episodes under a new protocol using a monoclonal antibody daclizumab in the induction phase of immunosuppressive therapy. The study group B (26patients) was given daclizumab (1mg/kg), the controlgroup A (25patients) was treated without daclizumab.During the first two months there was a significant lower incidence and/or severity of rejection episodes in the daclizumab group with p<=0,0016, 0,001 and 0,005 respectively. Induction therapy with daclizumab significantly reduces the incidence of acute rejection episodes during the first two posttransplant months in heart transplant recipients. It does not increase the risk of infection.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FA - Cardiovascular diseases including cardio-surgery

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2005

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of transplantation

ISSN

1425-9524

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

3

Country of publishing house

PL - POLAND

Number of pages

6

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—